SavicaV., BellinghieriG., SantoroD.it Is it time to modify the target range for serum phosphorus levels in chronic kidney disease (CKD)?J Ren Nutr2010; 20(2): 65.
4.
KestembaumB., SampsonJ.N., RudserK.D.. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol2005; 16: 520–8.
5.
SavicaV., CalòL.A., MonardoP., CaldareraR., CavaleriA., SantoroD., MuracaU., MallamaceA., BellinghieriG.High phosphate content beverages in dialysis patients: relevance for hyperphosphatemia and cardiovascular risk. Nutr Metab Cardiovasc Dis2008; 18(8): 39–40.
6.
SavicaV., CalòL.A., MonardoP., SantoroD., MallamaceA., MuracaU., BellinghieriG.Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr2009; 19(1): 69–72.
SavicaV., CalòL.A., SantoroD., MonardoP., SantoroG., MuracaU., DavisPA, BellinghieriG.Salivary glands: a new player in phosphorus metabolism. J Ren Nutr2011; 21(1): 39–42.
9.
SavicaV., CalòL.A., CaldareraR., CavaleriA., GranataA., SantoroD., SavicaR., MuracaU., MallamaceA., BellinghieriG.Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol2007; 105(3): 52–5.
10.
SavicaV., CalòL.A., GranataA., CaldareraR., CavaleriA., SantoroD., MonardoP., SavicaR., MuracaU., BellinghieriG.A new approach to the evaluation of hyperphosphatemia in chronic kidney disease. Clin Nephrol2007; 68(4): 216–21.
